Molecular typing is based on molecular genetic testing and isn't however routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers of your tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 might be beneficial, but a